TRAX PDUFA date: FDA decision expected April 14, 2027

The FDA is expected to decide on this application from First Tracks Biotherapeutics, Inc. by the PDUFA target action date of April 14, 2027. For Conventional Chondrosarcoma No filing review issues identified by FDA with PDUFA goal date set for April 14. BLA filing. Extracted from: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.